Clinical Interests
Dr. Ataga’s clinical interest and expertise focuses on sickle cell disease and related hemoglobinopathies, thalassemia and other red blood cell disorders.

Research Interests
Dr. Ataga’s primary research interest is in the development of drug therapies for sickle cell disease. Over the past many years, he has led or collaborated in studies of novel drug therapies in sickle cell disease. He was the lead investigator in the clinical studies of senicapoc, a Gardos channel blocker, in patients with sickle cell disease. Dr. Ataga was also the lead investigator in the multicenter study of crizanlizumab, a humanized anti-P-selectin antibody, in sickle cell disease (Ataga KI et al, NEJM, 2017).